Authors: Nicholas M Mordwinkin Paul W Burridge Joseph C Wu
Publish Date: 2012/11/15
Volume: 6, Issue: 1, Pages: 22-30
Abstract
Drug attrition rates have increased in past years resulting in growing costs for the pharmaceutical industry and consumers The reasons for this include the lack of in vitro models that correlate with clinical results and poor preclinical toxicity screening assays The in vitro production of human cardiac progenitor cells and cardiomyocytes from human pluripotent stem cells provides an amenable source of cells for applications in drug discovery disease modeling regenerative medicine and cardiotoxicity screening In addition the ability to derive humaninduced pluripotent stem cells from somatic tissues combined with current highthroughput screening and pharmacogenomics may help realize the use of these cells to fulfill the potential of personalized medicine In this review we discuss the use of pluripotent stem cellderived cardiomyocytes for drug discovery and cardiotoxicity screening as well as current hurdles that must be overcome for wider clinical applications of this promising approach
Keywords: